Prenetics Global Limited has strategically divested its majority stake in ACT Genomics for approximately $46 million in cash, significantly bolstering its pro-forma cash reserves to $86 million and total short-term assets to $117 million, while maintaining a debt-free balance sheet. This move completes Prenetics' business transformation, allowing the company to simplify its investment focus on high-growth consumer health brands like IM8, CircleDNA, and Europa. This strategic pivot has already yielded strong results, with the company raising its FY2025 revenue outlook to $80-$100 million (excluding ACT Genomics), primarily driven by the exceptional performance of IM8, which has rapidly acquired over 55,000 customers and achieved a 91% subscription rate. Additionally, Prenetics retains a valuable $70 million stake in early cancer detection company Insighta and plans to explore innovative treasury management strategies, including digital asset adoption.